Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic
  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Marks a Major Step in Seamless Phase 2/3 Smoking Cessation Clinical Trial; Partners with Combat Stress to Treat PTSD among Veterans

  • Mydecine has summitted a pre-IND briefing package to the FDA in readiness for its phase 2/3 smoking cessation trial scheduled for Q2 2022
  • The study will be led by Dr. Matthew Johnson, with the placebo-controlled research being conducted at Johns Hopkins University
  • Mydecine also announced its partnership with Combat Stress to use psilocybin in a psychoactive-assisted psychotherapy PTSD treatment program for veterans
  • Combat Stress will also be one of several sites for the company’s upcoming clinical trials set to launch later in the year

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) plans to launch its seamless phase 2/3 smoking cessation clinical trial in the second quarter (“Q2”) of the 2022 financial year, with primary endpoints of three and six months. The study will build previous research conducted by Dr. Matthew Johnson, Ph.D., and his team at Johns Hopkins University. Their ongoing study is showing 59% of participants who received psychedelic-assisted therapy remained abstinent from smoking at 12 months. In comparison, only 28% of patients who received the transdermal nicotine patch remained abstinent (https://ibn.fm/KvEUG). 

In readiness for the trial, Mydecine has submitted a pre-Investigational New Drug (“IND”) briefing package to the United States Food and Drug Administration (“FDA”). The submission will allow the company to…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.